Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2011 Jul;70(7):596–609. doi: 10.1097/NEN.0b013e31822146ca

Figure 7.

Figure 7

Malignant rhabdoid tumors (MRT) express nucleophosmin (NPM). (A) NPM immunostaining of an atypical teratoid/rhabdoid (AT/RT) tumor demonstrating strong (3+) expression. (B) Semiquantitative estimation of NPM showed strong to weak expression in all AT/RT and non-CNS malignant rhabdoid tumor (MRT) cases. (C) Moderate (2+) expression of phosphorylated NPM (pNPM) in an AT/RT case. (D) Semiquantitative estimation of pNPM showed focal weak to moderate expression in AT/RT and non-CNS MRT cases. The y-axes in B and D represent semiquantitative measures of the product of staining intensity and percentage of positive cells in each case.